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Summary
 
Endogenously released or exogenously administered glucocorticosteroids are relevant hor-
mones for controlling inflammation. Only 11
 
b
 
-hydroxy glucocorticosteroids, but not 11-keto
glucocorticosteroids, activate glucocorticoid receptors. Since we found that glomerular mesan-
gial cells (GMC) express 11
 
b
 
-hydroxysteroid dehydrogenase 1 (11
 
b
 
-OHSD1), which intercon-
verts 11-keto glucocorticosteroids into 11
 
b
 
-hydroxy glucocorticosteroids (cortisone/cortisol
shuttle), we explored whether 11
 
b
 
-OHSD1 determines the antiinflammatory effect of gluco-
corticosteroids. GMC exposed to interleukin (IL)-1
 
b
 
 or tumor necrosis factor 
 
a
 
 (TNF-
 
a
 
) re-
lease group II phospholipase A2 (PLA2), a key enzyme producing inflammatory mediators.
11
 
b
 
-hydroxy glucocorticosteroids inhibited cytokine-induced transcription and release of
PLA2 through a glucocorticoid receptor–dependent mechanism. This inhibition was enhanced
by inhibiting 11
 
b
 
-OHSD1. Interestingly, 11-keto glucocorticosteroids decreased cytokine-
induced PLA2 release as well, a finding abrogated by inhibiting 11
 
b
 
-OHSD1. Stimulating
GMC with IL-1
 
b
 
 or TNF-
 
a
 
 increased expression and reductase activity of 11
 
b
 
-OHSD1. Sim-
ilarly, this IL-1
 
b
 
– and TNF-
 
a
 
–induced formation of active 11
 
b
 
-hydroxy glucocorticosteroids
from inert 11-keto glucocorticosteroids by the 11
 
b
 
-OHSD1 was shown in the Kiki cell line
that expresses the stably transfected bacterial 
 
b
 
-galactosidase gene under the control of a gluco-
corticosteroids response element. Thus, we conclude that 11
 
b
 
-OHSD1 controls access of 11
 
b
 
-
hydroxy glucocorticosteroids and 11-keto glucocorticosteroids to glucocorticoid receptors and
thus determines the anti-inflammatory effect of glucocorticosteroids. IL-1
 
b
 
 and TNF-
 
a
 
 upreg-
ulate specifically the reductase activity of 11
 
b
 
-OHSD1 and counterbalance by that mechanism
their own proinflammatory effect.
 
I
 
L-1
 
b
 
 and TNF-
 
a
 
 often act synergistically and cause a
wide array of in vitro and in vivo immune inflammatory
responses such as the secretion of phospholipase A2 (PLA2)
 
1
 
, a
key enzyme that releases arachidonic acid and therefore boosts
prostaglandin production and secretion (1–3). This inflam-
matory reaction is regulated by 11
 
b
 
-hydroxy glucocorti-
costeroids; for instance, glucocorticoid deficiency increases,
whereas physiological and pharmacological doses of gluco-
corticosteroids suppress the enhanced expression of group
II PLA2 during inflammation (4–7). The biological activity
of glucocorticosteroids depends on their dose, metabolism,
local access to their cognate receptors, and on the respon-
siveness of the target cells (8, 9). Traditionally the 11-keto–
glucocorticosteroid molecules are believed to have hardly
any biological activity because of their negligible affinity to
glucocorticoid receptors. In the present investigation, we
demonstrate that during inflammation, 11-keto steroids exhibit
antiinflammatory properties. This effect is dependent on the
activity of the enzyme 11
 
b
 
-hydroxysteroid dehydrogenase
(11
 
b
 
-OHSD), which interconverts the 11-keto and the corre-
sponding 11
 
b
 
-hydroxy glucocorticosteroids by the so-called
cortisone/cortisol shuttle (8, 10–15; Fig. 1).
Two isoenzymes accounting for 11
 
b
 
-OHSD activity
have been cloned and characterized: 11
 
b
 
-OHSD1 (11) is
dependent on the reduced form of nicotinamide adenine
dinucleotide phosphate [NADP(H)] and catalyses both the
oxidation and the reduction reactions, whereas 11
 
b
 
-OHSD2
requires nicotinamide adenine dinucleotide (NAD) as a co-
factor and exhibits only oxidative activity (12). The biologi-
cal role of 11
 
b
 
-OHSD2 is most likely to provide selective
access of aldosterone to the mineralocorticoid receptor by
inactivating cortisol (8, 13–15). The absence of 11
 
b
 
-
 
1
 
Abbreviations used in this paper:
 
 dCTP, desoxy CTP; GA, glycyrrhetinic
acid; GAPDH, glyceraldehydephosphate dehydrogenase; GMC, glomer-
ular mesangial cells; mRNA, messenger RNA; NAD, nicotinamide ade-
nine dinucleotide; NADP, NAD phosphate; NADPH, reduced form of
NADP; OHSD, hydroxysteroid dehydrogenase; PLA2, phospholipase
A2; RT-PCR, reverse transcribed PCR.
  
190
 
TNF-
 
a
 
, IL-1
 
b
 
, and Glucocorticosteroids
 
OHSD2 results in apparent mineralocorticoid excess with
hypertension and hypokalemia. Because specific inactivation
of cortisol is relevant only in distal tubular cells of the kid-
ney, salivary glands, and colon (the target cells of aldoste-
rone), 11
 
b
 
-OHSD2 is almost exclusively expressed in this
subset of cells. 11
 
b
 
-OHSD1, on the other hand, is expressed
in a wide variety of tissues, but its function is still not clear.
In this report, we studied the role of 11
 
b
 
-OHSD1 in
glomerular mesangial cells (GMC). These proinflammatory
cells were chosen because they play a pivotal role in certain
forms of glomerular diseases. During inflammation, these
cells release active substances such as enzymes, vasoactive en-
dobiotics, extracellular matrix components, prostaglandins,
and cytokines such as IL-1
 
b
 
 and TNF-
 
a
 
, which cause local
glomerular tissue damage (6, 16–18). In the present investi-
gation, it is demonstrated that the activity of the 11
 
b
 
-
OHSD1 determines the antiinflammatory effect of 11
 
b
 
-
hydroxy glucocorticosteroids and that the proinflammatory
endobiotics IL-1
 
b
 
 and TNF-
 
a
 
 upregulate the reductase ac-
tivity of 11
 
b
 
-OHSD1, and thus, these cytokines display a
dual mode of action in that they induce concomitantly in-
flammation and an antiinflammatory response.
 
Materials and Methods
 
Supplies.
 
For cell culture and 11
 
b
 
-OHSD assay, corticosterone,
dehydrocorticosterone, glycyrrhetinic acid, transferrin, and insu-
lin were obtained from Sigma Chemical Co. (Buchs, Switzer-
land), and NAD phosphate (NADP), NADPH, and NAD were
from Boehringer Mannheim (Rotkreuz, Switzerland). [1,2,6,7
 
3
 
H]corticosterone with a specific activity of 83 Ci/ mM and
[
 
3
 
H]oleic acid (specific activity 10 Ci/mM) were purchased from
Amersham Intl. (Buckinghamshire, U.K.). [
 
3
 
H]dehydrocortico-
sterone was prepared as already described (19). Bicinchonic acid
protein assay reagent was from Pierce Chemical Co. (Rockford,
IL). Triton X-100 and TLC plates (60 fluorescence indicator 254)
coated with silica gel were from Merck (Schweiz) AG (Dietilcon,
Switzerland). RPMI-1640, penicillin G (100,000 U/liter) and
 
streptomycin sulfate (100,000 
 
m
 
g/liter) were obtained from GIBCO
BRL (Basel, Switzerland); FCS was from Biological Industries
(France). Tissue culture plates (24-well plates) were obtained
from Becton Dickinson Labware (Basel, Switzerland), IL-1
 
b
 
 and
TNF-
 
a
 
 were from Pharma Biotechnologie (Hannover, Ger-
many), and forskolin was from Calbiochem-Novabiochem (Luzern,
Switzerland). RU 486 was a gift from Dr. B. Stadler (Institute of
Immunology, Berne, Switzerland). For reverse transcription and
polymerase chain reaction, deoxynucleotides (dNTPs), RNAse in-
hibitor, avian myeloblastosis virus reverse transcriptase, and BSA
were obtained from Boehringer Mannheim. Primers were ordered
from Microsynth (Balgach, Switzerland) and Thermus aquaticus
DNA polymerase from Perkin-Elmer Cetus Instrs. (Norwalk, CT).
The enhanced chemiluminescence detection kit was purchased
from Amersham Intl.
 
Cell Cultures.
 
GMC were cultured from isolated rat (Sprague-
Dawley) glomeruli (20). In brief, the cells were grown in RPMI-
1640 supplemented with 10% FCS, penicillin (100,000 U/liter),
streptomycin (100,000 
 
m
 
g/liter), transferrin (5 mg/liter), insulin
(5 mg/liter), and sodium selenite (5 
 
m
 
g/liter). For the experi-
ments, passages 20–30 were used. For 11
 
b
 
-OHSD assays, confluent
GMC cultures in 15-mm–diameter wells were incubated with
500 
 
m
 
l RPMI-1640 medium containing 10% FCS and increasing
concentrations of IL-1
 
b
 
, TNF-
 
a
 
, or both for 48 h in a CO
 
2
 
 in-
cubator maintained at 37
 
8
 
C. The medium was removed and con-
version by stimulated GMC of corticosterone to dehydrocor-
ticosterone and dehydrocorticosterone to corticosterone was
analyzed in situ by incubating the cells for 4 h with 200 
 
m
 
l me-
dium containing 5 nCi [
 
3
 
H]corticosterone or [
 
3
 
H]dehydrocorti-
costerone and 0.5 
 
m
 
M corticosterone or dehydrocorticosterone.
After incubation, the medium was extracted with 200 
 
m
 
l ethyl ace-
tate and TLC were performed as described below. Protein was
extracted from the cells by adding 200 
 
m
 
l 0.4 N NaOH at 37
 
8
 
C
for 1 h after neutralization with the same volume of 0.4 N HCl.
Specific activity was expressed as the percentage of conversion of
corticosterone to dehydrocorticosterone, and dehydrocorticoste-
rone to corticosterone, respectively, per milligram of total protein
during 4 h. For PLA2 assays, confluent GMC cultures in 15-mm–
diameter wells were incubated with 500 
 
m
 
l RPMI-1640 medium
containing 10% FCS and 1 nM of IL-1
 
b
 
 with and without indi-
cated concentrations of corticosterone and/or glycyrrhetinic acid,
and forskolin or RU 486. 24 h later, the medium was removed,
centrifuged for 5 min at 4,000 rpm and used for PLA2 assay.
COS-1 cells were cultured and transfected with the cDNA of
11
 
b
 
-OHSD1 as previously described (19).
Kiki cells are a cell line derived from rat embryonal 3Y1 cells (21).
They were engineered to carry a bacterial 
 
b
 
-galactosidase gene
(lacZ) under control of the mouse mammary tumor virus pro-
moter. This promoter contains essential glucocorticoid response
elements. Thus, Kiki cells express 
 
b
 
-galactosidase when exposed
to sufficient doses of 11
 
b
 
-hydroxy steroids. Kiki cells were cul-
tured in DMEM supplemented with 10% FCS, 60 mg/liter kana-
mycin, and 30 mg/liter hygromycin B. For steroid activity assays,
the cells were incubated for 72 h with a combination of steroids
and cytokines, and then subjected to the in situ 
 
b
 
-galactosidase
assay as described (21).
 
Assay for 11
 
b
 
-OHSD1.
 
The assay was performed as previ-
ously described by Monder et al. (22). Oxidation or reduction at
C-11 was determined by measuring the rate of conversion of cor-
ticosterone to 11-dehydrocorticosterone in the presence of NADP
or dehydrocorticosterone to corticosterone in the presence of
NADPH. GMC were extracted with 10 mM Tris-HCl (pH 7.5),
5 mM EDTA (pH 8), 1% Triton X-100, 2 mM PMSF, and 100
Figure 1. Cortisone/cortisol shuttle. The endogenous hormones corti-
sol and corticosterone, as well as the pharmacologically used prednisolone,
are biologically active 11b-hydroxy glucocorticosteroids because they can
bind to the cognate receptor. The corresponding 11-keto glucocorticoids
cortisone, dehydrocorticosterone, and prednisone are unable to do so.
The enzyme 11b-OHSD1 converts 11-keto glucocorticosteroids to 11b-
hydroxy glucocorticosteroids and vice versa, and thus regulates local in-
tracellular access of the steroids to the receptors. 11b-OHSD activity can
be inhibited by glycyrrhetinic acid, a compound found in licorice and an-
ise. Corticosterone and dehydrocorticosterone differ from cortisol and
cortisone because of the absence of a hydroxyl group at position C17,
whereas prednisolone and prednisone have an additional double bond in the
A ring. 
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m
 
g total protein were used for the reaction. The assay was per-
formed in 0.25 mM NADP or NADPH, 100 mM Tris (pH 8.3),
10 nCi [
 
3
 
H]corticosterone or [
 
3
 
H]dehydrocorticosterone, and 5 
 
m
 
M
corticosterone or dehydrocorticosterone. Samples were incubated
for 3 h at 37
 
8
 
C, reaction was stopped on ice, and steroids were
extracted with 500 
 
m
 
l ethyl acetate. The organic layer was sepa-
rated by centrifugation at 13,000 rpm and evaporated under a
stream of nitrogen. The steroid residue was dissolved in 20 
 
m
 
l
methanol containing a mixture of 20 
 
m
 
g each of unlabeled corti-
costerone and dehydrocorticosterone. This was quantitatively
transferred to thin-layer plates and developed in chloroform-
methanol (90:10 vol/vol). The spots corresponding to the steroids
were located under a UV lamp, cut out, transferred to scintilla-
tion vials, and counted in scintillation fluid in a Kontron (Zurich,
Switzerland) Betamatic fluid scintillation counter. Specific activ-
ity was expressed as nanomolar of product formed per microgram
protein per hour.
 
Assay for 11
 
b
 
-OHSD2.
 
The assay was performed as previ-
ously described by Albitson et al. (12). Homogenization of cells
for measurement of 11
 
b
 
-OHSD2 activity was performed in ho-
mogenization buffer containing 250 mM sucrose and 10 mM
Tris-HCl (pH 7.5). Protein extract was incubated for 3 h at 37
 
8
 
C
with 1 mM NAD, 10 nM corticosterone, and 50 nCi [
 
3
 
H]corti-
costerone in 500 
 
m
 
l homogenization buffer. The subsequent steps
were the same as those described for 11
 
b
 
-OHSD1.
 
Assay for 17
 
b
 
-OHSD.
 
The stimulation experiments were per-
formed in parallel with those for 11b-OHSD1 measurements. 17b-
OHSD activity was performed as already described (23) by mea-
suring in situ the conversion of estradiol to estrone or estrone to
estradiol. GMC were incubated for 4 h with 200 ml medium
containing 5 nCi [3H]estradiol or [3H]estrone and 0.5 mM estra-
diol or estrone. After incubation, the medium was extracted with
1 vol diethyl ether and frozen. The unfrozen organic layer was
poured into a fresh tube, evaporated under a stream of nitrogen,
and TLC were performed in 4:1 dichloromethane/ethyl acetate,
using 20 mg unlabeled estradiol and estrone. The next steps were
the same as for 11b-OHSD1.
Assay for PLA2 Activity. [3H]oleic acid–labeled Escherichia coli
were prepared as already described (24, 25). PLA2 was assayed us-
ing [3H]oleate-labeled, autoclaved E. coli as the substrate (26).
The reaction mixture of 350 ml contained 100 mM Tris-HCl
(pH 8.0), 5 mM Ca21, 2.85 3 108 cells of autoclaved E. coli (cor-
responding to 10,000 cpm and 5.0 nm lipid phosphorus), and tis-
sue acid extracts or supernatants of GMC. The amount of protein
was chosen such that 6–15% hydrolysis of substrate was obtained
when incubated at 378C for 2 h. The reaction was stopped by
adding 100 ml of 2N HCl. 100 ml of fatty acid–free BSA (100
mg/ml) was added, and the tubes were vortexed and centrifuged
at 13,000 rpm for 5 min. An aliquot (140 ml) of the supernatant
containing released [3H]oleic acid was mixed with scintillation
cocktail and counted in a liquid scintillation counter.
Reverse Transcription of Messenger RNA and PCR. Total RNA
was extracted from GMC after the guanidium thiocyanate method
(27). The RNA concentration was determined by measuring the
absorption at 260 nm and its quality was controlled by loading 1 mg
on a 1% formaldehyde gel. Reverse transcription was performed
in 20 ml containing 50 mM Tris-HCl (pH 8.2), 6 mM MgCl2, 10
mM dithiothreitol, 100 mM NaCl, 200 mM dNTPs, 11 U of ribo-
nuclease inhibitor RNAsin, 1 U avian myeloblastosis virus reverse
transcriptase, 10 pmol 39 primer of the corresponding cDNA po-
sition (852–873 for 11b-OHSD1, 1271–1295 for 11b-OHSD2,
335–359 for group I PLA2, 695–719 for group II PLA2, 980–
1004 for the internal standard glyceraldehydephosphate dehydro-
genase [GAPDH]), and 2 mg total RNA (4, 11, 12, 24, 28). Ini-
tially, the 39 primer was incubated with total RNA for 5 min at
658C and cooled at room temperature for 15 min. The remaining
reaction components were added and incubated for 1 h at 428C.
PCR was performed in a total volume of 30 ml with 10 mM
Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 200 mM dNTPs,
10 pmol of the appropriate 39 and 59 cDNA primers (59 primer:
117–137 for 11b-OHSD1, 381–406 for 11b-OHSD2, 38–62 for
group I PLA2, 58–82 for group II PLA2 II, 66–90 for GAPDH),
6 mg BSA, 1 mCi [a-32P]desoxy CTP (dCTP), 2 ml of reverse tran-
scribed cDNA, 1 U Thermus aquaticus DNA polymerase. The
mixture was overlaid with mineral oil and cDNA was amplified
with a DNA thermal cycler (Perkin Elmer Cetus) for 35 cycles.
The amplification profile involved denaturation at 948C for 1
min and 15 s, primer annealing at 608C for 2 min, and elongation
of annealed primers at 728C for 3 min. 10 ml of each PCR reac-
tion mixture was mixed with 2 ml of sixfold concentrated loading
buffer and applied on a 0.9% agarose gel containing ethidium
bromide. Electrophoresis was carried out with a constant voltage
of 8 V/cm for 40 min. Bands were visualized under UV light and
excised from the gel. The radioactivity was measured in a liquid
scintillation b-counter using a Cerenkov program.
Western Blot Analysis. Electrophoresis was performed using a
12.5% polyacrylamide gel under reducing conditions. Prestained
protein standards were used as markers. Probes (25 mg of total
protein) were heated along with SDS sample buffer at 958C for
15 min. After electrophoresis, the gel was equilibrated in transfer
buffer (20 mM Tris, 190 mM glycine, 20% methanol) for 10 min.
The transfer of protein to an Immobilon membrane (Millipore
Corp., Bedford, MA) was performed with a constant voltage of
60 V for 1 h on ice. The membrane was blocked in 5% BSA in
PBS for 2 h, washed with PBS, and incubated over night with a
rabbit polyclonal antibody for 11b-OHSD1 (gift from Carl Mon-
der, The Population Council, New York, NY). The Immobilon
membrane was washed with PBS, saturated again for 2 h in 5%
BSA, and incubated for 1 h at room temperature with a goat
anti–rabbit IgG horseradish peroxidase conjugate (Bio Rad Labs.,
Hercules, CA). After washing, the detection was performed with
the enhanced chemiluminescence kit. The bands on the x-ray
film were scanned with a transmittance scanning densitometer
(Scanalytics, Billerica, MA).
Figure 2. GMC contain 11b-
OHSD1 and group II PLA2
transcripts. (Top) Agarose gel
electrophoresis of PCR products
of GMC. The mRNA of PLA2
and 11b-OHSD isoenzymes
was reverse transcribed from 5
mg of total RNA using appropri-
ate primers, and one sixth of that
mixture was amplified by PCR.
M, molecular weight marker (l-
HindIII, GIBCO BRL); b, blank
(no cDNA); A1, group I PLA2;
A2, group II PLA2; B1, 11b-
OHSD1;  B2, 11b-OHSD2.
(Bottom) Incorporation of [a32P]-
dCTP (cpm) into cDNA of
PLA2 and 11b-OHSD. Each
value represents the average of
two determinations. These re-
sults indicate negligible transcription of group I PLA2 and 11b-OHSD2,
and substantial transcription of group II PLA2 and 11b-OHSD1.192 TNF-a, IL-1b, and Glucocorticosteroids
Results
To establish the presence of 11b-OHSD1 and 11b-
OHSD2, as well as PLA2 group I and group II, their mes-
senger RNA (mRNA) levels were measured in GMC by
reverse transcribed PCR (RT-PCR) using specific primers.
The PCR products on the gel revealed signals for group II
PLA2 and 11b-OHSD1, but no signal for group I PLA2
(pancreatic), and only a very faint signal for 11b-OHSD2
(Fig. 2, top). These signals were also quantified by including
[a32P]-dCTP nucleotide during PCR (Fig. 2, bottom).
Oxidation of the hydroxyl group of corticosterone and
reduction of the keto group of dehydrocorticosterone by
11b-OHSD1 were measured using NADP and NADPH as
cofactors, respectively, in Triton X-100 extracts of GMC.
The enzyme activity was plotted as a function of the
amount of protein (Fig. 3). A dose-dependent increase in
the oxidation (Fig. 3, left) and reduction (Fig. 3, right) activ-
ity was observed. Glycyrrhetinic acid (GA), a known in-
hibitor of 11b-OHSD1 and 11b-OHSD2 (12, 29), com-
pletely inhibited oxidation and reduction activity of GMC
11b-OHSD1. The GMC extract had no 11b-OHSD2 ox-
idation activity with NAD as cofactor (data not shown), an
observation in line with the weak signal observed by RT-
PCR. It has to be noted that 11b-OHSD2 has only oxida-
tion and no reduction activity (12).
During glomerular inflammation, PLA2 levels rise
sharply in GMC after stimulation with IL-1b, TNF-a, or
forskolin (30–32). Therefore, we studied the role of 11b-
OHSD1 on the inhibitory effect of glucocorticoids on
PLA2. For that purpose, GA was used to modulate the ac-
tivity of 11b-OHSD1. The level of group II PLA2 was first
assessed by RT-PCR (Fig. 4). Stimulation of GMC with
IL-1b markedly enhanced the level of group II PLA2. The
rise was less pronounced in the presence of corticosterone
and was diminished further when GA was added. GA
alone, however, does not affect group II PLA2 expression
induced by IL-1b. The quantitatively assessed mRNA con-
tent of GAPDH in GMC was not affected in these different
experiments (data not shown).
Figure 3. GMC contain 11b-
OHSD1 activity. The amount of
protein extract from GMC ver-
sus 11b-OHSD1 oxidation (left)
and reduction (right) activity is
displayed. Enzyme activity is ex-
pressed as percentage of substrate
converted into product in 3 h.
Closed and open circles repre-
sent values of 11b-OHSD1 ac-
tivity without and with 5 mM
glycyrrhetinic acid, respectively.
Each value is the average (6 SEM)
of triplicate determinations. Both
oxidation and reduction activi-
ties increased with increasing
amounts of the protein extracts.
Glycyrrhetinic acid completely
abrogated both activities.
Figure 4. Inhibition of 11b-
OHSD1 activity by GA enhances
the ability of corticosterone to
decrease IL-1b–induced PLA2
mRNA levels. Agarose gel of
PCR products of group II PLA2
and GAPDH from GMC stimu-
lated with IL-1b and modulated
by corticosterone (Cort) and GA.
Lane B indicates the PCR blank
and lane M the molecular weight
marker. Lanes a–h in the upper
panel correspond with the col-
umns in the lower panel. In the
lower panel, each value repre-
sents the average (6 SD) of three
determinations. Corticosterone
was dissolved in methanol (m)
and GA in DMSO (d). These sol-
vents were also added whenever
corticosterone and/or GA were
not used. GA increased the ca-
pacity of corticosterone to inhibit
IL-1b–stimulated expression of
group II PLA2 (e). GA itself had
no effect (f and h) and corticosterone reduced only negligibly the mRNA
content of unstimulated GMC (g).
Figure 5. GA enhances the
ability of corticosterone (Cort) to
inhibit  IL-1b– and forskolin–
induced phospholipase (PLA2)
activity. (Top) GMC were incu-
bated for 48 h with combinations
of IL-1b (5 nM), corticosterone
(50 nM), and glycyrrhetinic acid
(5 mM), and PLA2 assays were
performed. Results represent
the mean (6 SD) of three assays.
(Bottom) Inhibition of group II
PLA2 enzyme activity in forsko-
lin stimulated GMC. Each col-
umn represents the mean (6 SD)
of three determinations. The in-
hibition of the enzyme activity
by corticosterone was enhanced
by the addition of GA.193 Escher et al.
In line with these observations, the enzymatic activity of
PLA2 increased upon stimulation with IL-1b or forskolin,
to be then decreased by the action of corticosterone and
corticosterone combined with GA (Fig. 5). Corticosterone
reduced the IL-1b–stimulated PLA2 enzyme activity by
60% and corticosterone in combination with GA dimin-
ished the activity by 90% (Fig. 5, top). GA alone did not al-
ter the secretion of PLA2 induced by IL-1b (Fig. 5, top).
Similar results were obtained when forskolin, instead of
IL-1b, was used for stimulaton of group II PLA2 activity
(Fig. 5, bottom).
To establish whether the inhibiton of group II PLA2 en-
zyme by corticosterone is mediated through glucocorticoid
receptors, the PLA2 activity was assayed in the presence of
the glucocorticoid antagonist RU 486. As shown in Fig. 6,
the effect of corticosterone was diminished by increasing
concentrations of RU 486, indicating that corticosterone
exerts its effect through glucocorticoid receptors.
Since it was shown previously that IL-1b increased cor-
ticosteroid levels, the hypothesis was tested whether IL-1b
and TNF-a regulate the 11b-OHSD1 (33, 34). For that
purpose, GMC were incubated with TNF-a, IL-1b, or a
combination of both, and the mRNA content was quanti-
fied by RT-PCR for 11b-OHSD1 (Fig. 7, top). Both IL-1b
and TNF-a only slightly enhanced the mRNA content in
GMC. The combination of both, in contrast, yielded a
strong additive effect (Fig. 7, top). The increased mRNA
content of GMC was reflected by a sharp increase in the
amount of 11b-OHSD1 protein (Fig. 7, bottom). The cy-
tokine-induced increase of protein levels was more marked
than the effect on steady-state mRNA levels, suggesting
that the modulation may take place mainly at the transla-
tional level. When the specific activity of 11b-OHSD1 was
analyzed, no change was seen with respect to oxidation (re-
sults not shown). However, the reductive activity of 11b-
OHSD1 increased as a function of the concentrations of
IL-1b and/or TNF-a (Fig. 8). The combination of TNF-a
and IL-1b stimulated the reductive activity more than ei-
ther of the cytokines added alone; this was shown when ei-
ther increasing concentrations of TNF-a or IL-1b were
used, or when a fixed amount of TNF-a with an increas-
ing amount of IL-1b were given to the cell cultures (Fig.
8). A similar pattern was observed when the specific activ-
ity (percentage of conversion of dehydrocorticosterone to
corticosterone per milligram protein per 4-h period) was
calculated (data not shown). To exclude that the increased
reductive activity after stimulation with cytokines was due
to an increased availability of cofactors, incubations of stim-
ulated GMC with dehydrocorticosterone in the presence
of 5 mM NADPH were performed. The results from these
studies revealed that the increased reductase activity in-
duced by cytokines was not attributable to a higher avail-
ability of NADPH (data not shown).
Besides IL-1b and TNF-a, other cytokines such as IL-3
and IL-6, and other stimulating agents including platelet-
derived growth factor, PMA, and forskolin were added to
the GMC cultures. These agents exhibited neither an in-
crease nor a decrease of the oxidative or reductive activity of
11b-OHSD1. To exclude a nonspecific effect of TNF-a
and/or IL-1b on oxidoreductase activity in general, the ac-
tivity of 17b-hydroxysteroid dehydrogenase was deter-
mined in GMC with and without the addition of TNF-a
and IL-1b using estradiol and estrone as substrates. The ac-
tivity of 17b-OHSD was not affected by these cytokines.
Thus, the enhancement of 11b-OHSD1 by IL-1b and
TNF-a is specific.
The biological relevance of the increased reductase ac-
tivity of 11b-OHSD1 after stimulation with IL-1b and/or
TNF-a was assessed first on the inhibition of PLA2 activity
in GMC. Unstimulated GMC or GMC treated with GA
alone or with the 11-keto–glucocorticosteroid dehydro-
corticosterone alone displayed only background PLA2 ac-
tivity (Fig. 9). Stimulation of GMC with IL-1b enhanced
PLA2 production at least fivefold. Dehydrocorticosterone
reduced the IL-1b–induced PLA2 activity. This effect was
abrogated with increasing concentrations of GA (Fig. 9). In
Figure 6. Corticosterone in-
hibits PLA2 expression through
glucocorticoid receptors. GMC
were incubated for 48 h with
combinations of IL-1b (5 nM),
corticosterone (50 nM), and in-
creasing concentrations of the
glucocorticoid antagonist RU
486 (RU). With increasing con-
centrations of RU 486, the in-
hibitory effect of corticosterone
was abolished. PLA2 was mea-
sured as the release of [3H]oleic
acid from E. coli membranes as
described. Each value is the aver-
age (6 SD) of triplicate determi-
nations.
Figure 7. (Top) IL-1b and
TNF-a increase steady-state
11b-OHSD1 mRNA in GMC.
The mean (6 SEM, n 5 6) in-
corporation of [a32P]-dCTP
(cpm) into cDNA of 11b-
OHSD1 after incubation of
GMC with TNF-a and/or IL-1b
was standardized to that of
GAPDH mRNA. (Bottom) IL-1b
and TNF-a increase 11b-OHSD1
protein levels in GMC. Western
blot analysis of 11b-OHSD1 in
GMC stimulated with and with-
out TNF-a and/or IL-1b. A,
11b-OHSD1 from COS cells
transfected with the cDNA of
11b-OHSD1;  B, GMC; C,
GMC with 5 nM of TNF-a;
D, GMC with 5 nM of IL-1b; E,
GMC with 5 nM of TNF-a and
5 nM of IL-1b. Quantification
of 11b-OHSD1 protein by densitometry analysis of the Western blot.
Without cytokines, no 11b-OHSD1 protein was detected. Both IL-1b
and TNF-a increased the relative transmission from a signal of below the
detection limit to a value of 2–4.194 TNF-a, IL-1b, and Glucocorticosteroids
a second set of experiments, the relevance of the intercon-
version of biologically inactive 11-keto glycocorticosteroids
into active 11b-hydroxy glucocorticosteroids was demon-
strated in the Kiki cell line (21). We found that Kiki cells
contain high levels of 11b-OHSD1, but low levels of 11b-
OHSD2 transcripts (data not shown). TNF-a and IL-1b
induce the reductase activity of 11b-OHSD1 in these cells
(data not shown). Kiki cells express the bacterial b-galac-
tosidase gene under the control of glucocorticoid-respon-
sive elements of the mouse mammary tumor virus promoter.
This cell line therefore expresses b-galactosidase only when
biologically active 11b-hydroxy glucocorticosteroids are
present. The experiments in Fig. 10 demonstrate that al-
though 11b-hydroxy glucocorticosteroids directly drive gene
expression, 11-keto glucocorticosteroids are unable to do
so unless the cells are concomitantly stimulated by IL-1b.
This effect is mediated by 11b-OHSD activity, because it
can be abolished with GA in a dose dependent fashion (Fig.
10 b). Furthermore, this effect is specific for 11-keto gluco-
corticosteroids as cortexolone, a steroid without a functional
group at position 11, displays an 11b-OHSD– and cyto-
kine–independent constitutive activity, albeit weak (Fig. 10
a) The relevance of the conversion of cortisone to cortisol
was furthermore shown when these two endogenous glu-
cocorticosteroids are present in the low physiological con-
centration range using Kiki cells (data not shown).
Discussion
The present study revealed for the first time 11b-OHSD
activity in GMC. The activity was attributable to 11b-
OHSD1 as shown by measurement of mRNA, protein, and
activity using NADP as a cofactor. The absence of appre-
ciable expression of 11b-OHSD2 in GMC is in line with
previous immunohistochemical data on kidney cortex (35,
36) showing only a weak staining for 11b-OHSD2 in the
visceral epithelial cells of the outer capillary loop of the
glomerulus.
Figure 8. IL-1b und TNF-a increase 11b-OHSD1 reductase activity
in GMC. The percentage of conversion of dehydrocorticosterone to cor-
ticosterone was determined as a function of increasing concentrations of
TNF-a (black columns), IL-1b (hatched columns), TNF-a and IL-1b com-
bined (stippled columns), and of a fixed amount of TNF-a (5 nM) in the
presence of increasing concentrations of IL-1b (white columns). A dose-
dependent increase in the reductive activity was observed. Each column
represents the mean (6 SD) of three determinations.
Figure 9. The 11-keto–gluco-
corticosteroid dehydrocorticos-
terone inhibits IL-1b–induced
PLA2 release by a process that
can be inhibited by GA. PLA2
activity was measured as the re-
lease of [3H]oleic acid from E.
coli membranes as described. Re-
sults represent the mean value
(6 SD) of three independent as-
says. GA, 0.1, 1.0, 10 mM; DCS,
dehydrocorticosterone, 0.1 mM;
IL-1b, 5 nM. GMC were treated with GA alone, DCS alone, IL-1b
alone, IL-1b and DCS, IL-1b, and DCS and different concentrations of GA.
Figure 10. (a) 11-keto glucocorticosteroids are converted into active
compounds and drive glucocorticoid-dependent gene expression in Kiki
cells. Kiki cells were incubated with 11b-hydroxy glucocorticosteroids (far
left histogram), the corresponding 11-keto glucocorticosteroids alone (mid-
dle left historgram), and the 11-keto glucocorticosteroids with IL-1b in ab-
sence (middle right histogram) and presence (far right histogram) of GA. Ex-
pression of the bacterial b-galactosidase reporter gene was detected by an
in situ assay as described (21). Results represent the mean value (6 SD) of
three independent assays. Concentrations: steroids, 0.1 mM; IL-1b, 5 nM;
GA, 50 mM. 11b-hydroxy glucocorticosteroids: cortisol, corticosterone,
prednisolone. 11-keto glucocorticosteroids: cortisone, dehydrocorticoste-
rone, prednisone. Cortexolone, included in both keto and hydroxy groups,
does not carry a functional group at position 11, and is therefore not a
substrate for 11b-OHSD1. (b) Effect of GA on conversion of prednisone
(Pn) into prednisolone (Po). Kiki cells were incubated in the presence of
0.1 mM prednisolone alone (column 1), 0.1 mM prednisone alone (col-
umn 2), 0.1 mM prednisone 1 5 nM IL-1b without GA (column 3), and
with 0.1, 1.0, and 10 mM GA (columns 4, 5, and 6). Results represent the
mean value (6 SD) of three determinations.195 Escher et al.
The impact of 11b-OHSD1 on glucocorticoid action
during inflammation was analyzed by studying the cortico-
sterone-induced inhibition of group II PLA2 release in
GMC. As recently shown, GMC stimulated with IL-1b or
TNF-a enhance the eicosanoid formation concomittantly
with an increased 14-kD group II PLA2 gene expression
and secretion (30–32, 37). A similar effect was observed
when GMC were stimulated with forskolin (37, 38). For-
skolin and IL-1b stimulate PLA2 through two distinct
mechanisms: activation of adenyl cyclase and protein kinase
C (38). The enhanced expression of PLA2 in inflammation
is suppressed by glucocorticosteroids (39). In the present
study, the inhibitory effect of corticosterone on the release
of group II PLA2 stimulated by IL-1b or forskolin was en-
hanced by inhibiting the 11b-OHSD1 by GA. This effect
was most likely mediated through glucocorticoid receptors
as shown by abrogating the glucocorticoid inhibitory effect
with RU 486. When GA was added to the GMC, no di-
rect inhibition of group II PLA2 transcription and release
was observed; the inhibitory effect of GA on PLA2 was
only detected in the presence of corticosterone. This indi-
cates that the previously reported antiinflammatory (40)
and antiallergic effects of GA (41), the active pharmacolog-
ical component of licorice (Glycyrrhiza glabra), is attribut-
able to an enhanced effect of endogenous glucocorticoids
as a consequence of the inhibition of 11b-OHSD.
GMC occupy a central position within the glomeruli
(16–18). They are important for the regulation of glomeru-
lar filtration rate, and furthermore, GMC participate in the
process of glomerular injury. For both processes, arachidonic
acid–derived metabolites are relevant. Group II PLA2 plays
a pivotal role for the arachidonic acid release. PLA2 is reg-
ulated by glucocorticosteroids, since glucocorticoid defi-
ciency enhances and pharmacological doses of glucocorti-
costeroids suppress group II PLA2 transcription (4, 6, 16).
This high sensitivity of group II PLA2 to exogenously pre-
scribed or endogenously released steroid hormones under-
lines the relevance of glucocorticoids in health and disease
states for prostaglandin release. The present study demon-
strates that not only the concentrations of the glucocorti-
costeroids but, in addition, the intracellular disposition de-
termines their antiinflammatory effect.
The addition of IL-1b and TNF-a enhanced the expres-
sion of 11b-OHSD1. The activity of the reductase, but not
that of the oxidase, of 11b-OHSD increased severalfold.
This observation has been made in two different cell lines.
The mechanism accounting for the enhanced reduction is a
specific phenomenon because the activity of another ox-
ido-reductase, the 17b-hydroxysteroid dehydrogenase, was
not affected by the cytokines. The enhanced activity of
11b-OHSD1 cannot be explained by mere proliferation of
the GMC induced by these cytokines, since the specific ac-
tivity of 11b-OHSD1 reductase increased and other GMC-
stimulatory agents did not enhance the 11b-OHSD1 reduc-
tive capacity in GMC. The increased reductive capacity is
biologically relevant as evidenced first by the activation of a
glucocorticosteroid response element–dependent reporter
gene by biologically inert 11-keto steroids such as corti-
sone, dehydrocorticosterone, or prednisone, and by the inhi-
bition of PLA2 through a glucocorticoid receptor–depen-
dent pathway by dehydrocorticosterone.
The mechanism for the enhanced reductive but not oxi-
dative activity, despite increased concentrations of 11b-
OHSD1 protein after stimulation with IL-1b and TNF-a,
is unknown. One possible mechanism is a different post-
translational modification. Such modifications exist for 11b-
OHSD1, as shown by Agarwal et al. who incubated TK-
143B human osteosarcoma cells transfected with the cDNA
of rat 11b-OHSD1 in the presence of the glycosylation in-
hibitor A1-tunicamycin and observed a 50% decrease in
dehydrogenase activity without affecting the reductase ac-
tivity (15). Similarly, in the present investigation, a clear
decline in the oxidase activity, but a less pronounced de-
cline in the reductase activity was seen when GMC were
incubated with A1-tunicamycin (data not shown). Thus, a
possible explanation of the altered oxidative/reductive ratio
induced by IL-1b and TNF-a, is a posttranslational modi-
fication. Nominally, however, we can not rule out the pos-
sibility that the relative increase in reductase activity relates
to the activation of a yet undiscovered and hypothetical
11b-OHSD3.
IL-1b and TNF-a often exert various synergistic in vitro
and in vivo effects including immune inflammatory responses
(1–3, 42, 43). In glomerular inflammation, increased ex-
pression of the inflammatory cytokines IL-1b and TNF-a
has been observed (44–49). IL-1b and TNF-a induce,
among others, contraction, proliferation, expression of re-
ceptors, and metabolic effects in GMC. The present novel
observation, that IL-1b and TNF-a modulate the 11b-
OHSD activity in such a way that the formation of active
11b-hydroxy glucocorticoids is favored, is a biologically
interesting phenomenon for the following reasons. First,
Besedowsky et al. and Sapolsky et al. presented evidence
for an interaction between IL-1b and glucocorticoids (33,
34). The injection of IL-1b activated the hypothalamo-
pituitary-adrenal axis with an enhanced secretion of adreno-
corticotropic hormone and corticosterone due to an IL-1–
stimulated release of corticotropin-releasing factor (33).
This observation was interpreted to mean that during in-
fections, cortisol or corticosterone appear in higher con-
centrations in serum to overcome the stress due to an infec-
tious challenge. The present observation that IL-1b favors
the formation of biologically active glucocorticoids during
inflammatory reactions within the target cells, is in line
with the seminal observations of Besedovsky et al. and Sa-
polsky et al. (33, 34). Second, IL-1b and TNF-a are known
to induce apoptosis in some cells (50, 51). Similarly, 11b-
hydroxy glucocorticosteroids induce apoptosis (52). Since
TNF-a and IL-1b stimulate the intracellular formation of
active glucocorticosteroids, they enhance their own apop-
toting potential. Third, inflammatory processes are limited
with respect to time in most situations. The mechanisms
accounting for such limitation are not completely under-
stood. Glucocorticosteroids are powerful inhibitors of IL-1b
and TNF-a secretion and of many of the inflammatory ef-
fects of these cytokines (53–56). IL-1b and TNF-a can196 TNF-a, IL-1b, and Glucocorticosteroids
mediate the onset of inflammation and, by inducing the re-
ductase activity of 11b-OHSD, enhance the GMC suscep-
tibility to glucocorticoids. It is interesting to note that the
two processes are temporally distinct. It has been already
shown that PLA2 levels rise sharply as early as 12 h after ex-
posure to proinflammatory cytokines (37). In contrast, we
have observed that a consistent increase in 11b-OHSD re-
ductase activity is detectable only after 24 h. After 1, 4, 6,
and 12 h, no significant increase in reductase activity was
detected (data not shown). By this dual action, IL-1b and
TNF-a may counterbalance their proinflammatory effect,
and contribute to the ultimately necessary arrest of inflam-
mation. A comparable dual effect of proinflammatory and
antiinflammatory actions has recently been described for
leukotriene B4 (57). Leukotriene B4 sustains and amplifies
inflammation, while concomitantly activating the peroxi-
some proliferator-activated receptor, which drives peroxi-
somal b-oxidative degradation of leukotriene B4 itself.
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